Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Here's Why You Should Steer Clear of Express Scripts for Now
by Zacks Equity Research
Express Scripts' (ESRX) loss of major customers, downbeat 2018 earnings guidance and selling of shares to Cigna make it lower its credibility as an investment pick.
Cardinal Health (CAH), CD&R to Jointly Invest in naviHealth
by Zacks Equity Research
Cardinal Health (CAH) intends to boost its acute-care program platform by jointly investing in the earlier acquired naviHealth along with Clayton, Dubilier & Rice.
SYK or SRDX: Which is a Better Medical Product Stock?
by Zacks Equity Research
Stryker (SYK) and Surmodics' (SRDX) strong fundamentals and rising share price make them close contenders.
3 Medical Instrument Stocks to Gain on Solid Market Prospects
by Zacks Equity Research
Here we take a peek at three Medical Instrument stocks that are likely to deliver strong returns in the days to come.
Here's Why You Should Buy Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian Medical's (VAR) solid product portfolio and strong global foothold make it a lucrative pick.
Medidata Solutions (MDSO) Rallies 10.4% on Solid Q1 Earnings
by Zacks Equity Research
Medidata Solutions (MDSO) reports strong Q1 earnings and solid growth across segments.
CVS Health's PBM Selling Season Remains Solid, Retail Grows
by Zacks Equity Research
CVS Health (CVS) significantly advances more than halfway through its 2019 renewals. Also, strong year-over-year Retail/LTC comparisons are encouraging.
Corindus Vascular Robotics (CVRS) Soars: Stock Adds 14.2% in Session
by Zacks Equity Research
Corindus Vascular Robotics (CVRS) saw a big move last session, as its shares jumped more than 14% on the day, amid huge volumes.
Cooper Companies (COO) Q2 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cooper (COO) witnesses strong growth across segments and geographies in fiscal Q2.
Bio-Rad Banks on Solid Global Scenario, Competition Rife
by Zacks Equity Research
Bio-Rad (BIO) delivers robust performance, primarily in North America, China and the Asia-Pacific region.
Why You Should Add IDEXX (IDXX) Stock to Your Portfolio?
by Zacks Equity Research
IDEXX's (IDXX) stellar performance is primarily driven by robust sales at the CAG (Companion Animal Group) business.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Genomic Health (GHDX) gains ground on promising reimbursement prospects for its Oncotype DX breast cancer test and solid international scenario.
ABMD or VAR: Which is a Better Medical Instrument Stock?
by Zacks Equity Research
It is pretty difficult for investors to choose from MedTech bigwigs Abiomed (ABMD) and Varian Medical (VAR) as both the companies are riding on solid estimate revision and other developments.
ResMed Reports Positive Results for Bilevel PAP Device Study
by Zacks Equity Research
Positive results from the Bilevel Rescue study are expected to boost the uptake of ResMed's (RMD) bilevel devices.
Varian to Demonstrate Brachytherapy Solutions Portfolio
by Zacks Equity Research
Varian (VAR) will demonstrate four brachytherapy solutions in the American Brachytherapy Society Annual Meeting in San Francisco.
STERIS (STE) Benefits From Core Business Expansion, Buyouts
by Zacks Equity Research
STERIS' (STE) strong organic growth across specialty services, life sciences and applied sterilization segments raises optimism on the stock.
Becton, Dickinson Ties Up With Helmer Scientific to Boost MMS
by Zacks Equity Research
Becton, Dickinson (BDX) aims to boost its MMS segment through the promotion of its Pyxis ES refrigerator.
Here's Why You Should Sell Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) faces sluggishness in the exam-gloves unit lately. Further, cutthroat competition in the niche space is a headwind.
Here's Why You Should Buy Abiomed (ABMD) Stock Right Now
by Zacks Equity Research
Abiomed's (ABMD) solid Impella product line and the inclusion in the S&P 500 connect make it a lucrative pick.
Amedisys (AMED) Buys Back 2.4M Shares From KKR, Stock Up
by Zacks Equity Research
Amedisys (AMED) works on its strategy to deploy capital in an accretive manner, maintaining low leverage and substantial borrowing capacity for future investment.
Medtronic's (MDT) CRHF Arm Growth Strong, Rising Costs a Woe
by Zacks Equity Research
The gradually stabilizing Cardiac Rhythm & Heart Failure (CRHF) market increases investor confidence in the Medtronic (MDT) stock.
NuVasive's (NUVA) Global Prospects Solid, Competition Rife
by Zacks Equity Research
NuVasive (NUVA) demonstrates strong sales growth across all geographies. Competitive landscape is a concern.
Here's Why You Should Invest in Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker's (SYK) focus on inorganic expansion and stellar Mako performance make the stock an attractive buy.
Boston Scientific Grows on New Products Amid Recall Issues
by Zacks Equity Research
Boston Scientific's (BSX) 2018 guidance raises optimism for the company's near-term prospects.
Bruker Unveils New Mass-Spectrometry Products, Boosts CALID
by Zacks Equity Research
Bruker's (BRKR) mass-spectrometry business within its CALID group rides high on strong sales performances in recent times.